NCT03076385View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Influenza
Interventions
BIOLOGICAL

VAL-506440

Escalating dose levels

OTHER

Placebo

Trial Locations (1)

Unknown

Berlin

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT03076385 - Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter